Prevention of opportunistic infections in immunosuppressed patients in the tropical Top End of the Northern Territory of Australia
DOI:
https://doi.org/10.33321/cdi.2003.27.87Keywords:
immunosuppression, strongyloides stercoralis, tuberculosis, scabies, chronic hepatitis B, melioidosisAbstract
The population of the Top End of the Northern Territory has a high incidence of several infections of particular significance in the immunosuppressed. The following protocol for evaluation and treatment of patients prior to immunosuppression was developed in order to reduce the incidence of serious opportunistic infections. The infections discussed are Strongyloides stercoralis, tuberculosis, scabies, chronic hepatitis B, melioidosis and other bacterial infections. We recommend that all patients planned to receive more than 0.5mg/kg/day of prednisolone for >14 days, or any more potent immunosuppressive drug, be evaluated and treated according to this protocol. Details of the rationale, evidence base, and proposed investigations and therapy for such patients are discussed. Commun Dis Intell 2003;27:526-532.
Downloads
References
Chu E, Whitlock W, Dietrich R. Pulmonary hyperinfection syndrome with Strongyloides stercoralis. Chest 1990;97:1475-1477.
Cruz T, Reboucas G, Rocha H. Fatal strongyloidiasis in patients receiving corticosteroids. N Eng J Med 1966;275:1093-1096.
Stuck AE, Minder CE, Frey FJ: Risk of infectious complications in patients taking glucocorticosteroids. [Review]. Rev Infect Dis 1989;11:954-963.
Aland K, Prociv P, Currie B, Jones H. Intestinal parasite infections and anaemia in an Arnhem Land Aboriginal Community. Abstract from Australian Tropical Health and Nutrition Conference, Brisbane, July 1997.
Fisher D, McCarry F and Currie B. Strongyloidiasis in the Northern Territory. Under-recognised and under-treated? Med J Aust 1993;159:88-90.
Anstey N, Bastian I, Dunckley H, Currie B. Systemic Lupus Erythematosus in Australian Aborigines: high prevalence, morbidity and mortality. Aust N Z J Med 1993;23:646-651.
Siddiqui A, Berk S. Diagnosis of Strongyloides stercoralis infection. [Review] Clin Infect Dis 2001;33:1040-1047.
Sato Y, Kobayashi J, Toma H, Shiroma Y. Efficacy of stool examination for detection of Strongyloides infection. Am J Trop Med Hyg 1995;53:248-250.
Pelletier LL. Chronic strongyloidiasis in World War II Far East ex-prisoners of war. Am J Trop Med Hyg 1984;33:55-61.
Nielsen PB, Mojon M. Improved diagnosis of Strongyloides stercoralis by seven consecutive stool specimens. Zentralbl Bakteriol Mikrobiol Hyg (A) 1987;263:616-618.
Genta RM. Predictive value of an enzyme-linked immunosorbent assay (ELISA) for the serodiagnosis of strongyloidiasis. Am J Clin Pathol 1988;89:391-394.
Kobayashi J, Sato Y, Toma H, Takara M and Shiroma Y. Application of enzyme immunoassay for postchemotherapy evaluation of human strongyloidiasis. Diagn Microbiol Infect Dis 1994;18:19-23.
Avery RK and Ljungman P. Prophylactic measures in the solid-organ recipient before transplantation. [Review] Clin Infect Dis 2001:33 (Suppl 1):S15-S21.
Huffam S, Currie B. Ivermectin for Sarcoptes scabiei hyperinfestation. Int J Infect Dis 1998;2:152-154.
Greene BM, Dukuly ZD, Munoz B, White AT, Pacque M, Taylor HR. A comparison of 6-, 12-, and 24-monthly dosing with ivermectin for treatment of onchocerciasis. J Infect Dis 1991;163:376-380.
Gann PH, Neva FA, Gam AA. A randomized trial of single- and two-dose ivermectin versus thiabendazole for treatment of strongyloidiasis. J Infect Dis 1994;169:1076-1079.
Marti H, Haji HJ, Savioli L, Chwaya HM, Mgeni AF, Ameir JS, et al. Comparative trial of a single-dose ivermectin versus three days of albendazole for treatment of Strongyloides stercoralis and other soil-transmitted helminth infections in children. Am J Trop Med Hyg 1996;55:477-481.
Datry A, Hilmarsdottir I, Mayorga-Sagastume R, Lyagoubi M, Gaxotte P, Biligui S, et al. Treatment of Strongyloides stercoralis infection with ivermectin compared with albendazole: results of an open study of 60 cases. Trans R Soc Trop Med Hyg 1994;88:344-345.
Currie B, Huffam S, O'Brien D, Walton S. Ivermectin for scabies. Lancet 1997;350:1551.
Fisher DA, Huffam SE. Management of chronic hepatitis B infection in remote-dwelling Aboriginals and Torres Strait Islanders: an update for primary healthcare providers. [Review] Med J Aust 2003:178:82-85.
Todo S, Demetris AJ, Van Thiel D, Teperman L, Fung JJ, Starzl TE. Orthotopic liver transplantation for patients with hepatitis B virus-related liver disease. Hepatology 1991;13:619-626.
Yagisawa T, Toma H, Tanabe K, Ishikawa N, Tokumoto N, Iguchi Y, et al. Long term outcome of renal transplantation in hepatitis B surface antigen-positive patients in the cyclosporin era. Am J Nephrol 1997;17:440-444.
Han DJ, Kim TH, Park SK, Lee SK, Kim SB, Yang WS, et al. Results on pre-emptive or prophylactic treatment with lamivudine in HBsAg (+) renal allograft recipients: comparison with salvage treatment after hepatic dysfunction with HBV recurrence. Transplantation 2001;71:387-394.
Antoine C, Landau A, Menoyo V, Duong JP, Duboust A, Glotz D. Efficacy and safety of lamivudine in renal transplant patients with chronic hepatitis B. Transplant Proc 2000;32:384-385.
Perrillo R, Rakela J, Dienstag J, Martin P, Wright T, Caldwell S, et al. Multicenter study of lamivudine therapy for hepatitis B after liver transplantation. Hepatology 1999;29:1581-1586.
Angus PW, McCaughan GW, Gane EJ, Crawford DH, Harley H. Combination low-dose hepatitis B immune globulin and lamivudine therapy provides effective prophylaxis against post-transplantation hepatitis B. Liver Transpl 2000;6:429-433.
Currie BJ, Fisher DA, Howard DM, Burrow JN, Lo D, Selva-Nayagam S, et al. Endemic melioidosis in tropical northern Australia-a ten year prospective study and review of the literature. Clin Infect Dis 2000;31:981-986
Suputtamongkol Y, Chaowagul W, Chetchotisakd P, Lertpatanasuwun N, Intaranongpai S, Ruchutrakool T, et al. Risk factors for melioidosis and bacteremic melioidosis. Clin Infect Dis 1999;29:408-413.
Gray N, Cass A, Lawton P, Snelling P. Infectious morbidity is greater in aboriginal renal transplant recipients. Presented at Transplant Society of Australia and NZ 20th ASM, Canberra, 2002. [Abstract].
Fox BC, Sollinger HW, Belzer FO, Maki DG. A prospective, randomised, double-blind study of trimethoprim-sulfamethoxazole for prophylaxis of infection in renal transplantation: clinical efficacy, absorption of trimethoprim-sulfamethoxazole, effects on the microflora, and the cost-benefit of prophylaxis. Am J Med 1990;89:255-274.
Downloads
Published
How to Cite
Issue
Section
Categories
License
Copyright (c) 2003 Communicable Diseases Intelligence
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
